Your browser doesn't support javascript.
loading
G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans.
Cardot-Ruffino, Victoire; Bollenrucher, Naima; Delius, Luisa; Wang, S Jennifer; Brais, Lauren K; Remland, Joshua; Keheler, C Elizabeth; Sullivan, Keri M; Abrams, Thomas A; Biller, Leah H; Enzinger, Peter C; McCleary, Nadine J; Patel, Anuj K; Rubinson, Douglas A; Schlechter, Benjamin; Slater, Sarah; Yurgelun, Matthew B; Cleary, James M; Perez, Kimberly; Dougan, Michael; Ng, Kimmie; Wolpin, Brian M; Singh, Harshabad; Dougan, Stephanie K.
Afiliación
  • Cardot-Ruffino V; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Bollenrucher N; Department of Immunology, Harvard Medical School, Boston, Massachusetts, USA.
  • Delius L; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Wang SJ; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Brais LK; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Remland J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Keheler CE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Sullivan KM; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Abrams TA; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Biller LH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Enzinger PC; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • McCleary NJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Patel AK; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Rubinson DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Schlechter B; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Slater S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Yurgelun MB; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Cleary JM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Perez K; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Dougan M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Ng K; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Wolpin BM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Singh H; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Dougan SK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
J Immunother Cancer ; 11(6)2023 06.
Article en En | MEDLINE | ID: mdl-37344102
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Protocolos de Quimioterapia Combinada Antineoplásica / Neutropenia Idioma: En Revista: J Immunother Cancer Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Protocolos de Quimioterapia Combinada Antineoplásica / Neutropenia Idioma: En Revista: J Immunother Cancer Año: 2023 Tipo del documento: Article